There is 1 publication for this product available. The Rabbit Polyclonal anti-Ret Proto-Oncogene antibody is suitable to detect Ret Proto-Oncogene in samples from Human. It has been validated for WB.
This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Immunogen
This RET antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1063-1093 amino acids from the C-terminal region of human RET.
RET
Reactivity: Human
WB, ELISA, IHC
Host: Rabbit
Polyclonal
unconjugated
Application Notes
WB: 1:1000
Restrictions
For Research Use only
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date
6 months
de Martimprey, Bertrand, Fusco, Santoro, Couvreur, Vauthier, Malvy: "siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma." in: Nucleic acids research, Vol. 36, Issue 1, pp. e2, (2008) (PubMed).
Target
Ret Proto-Oncogene (RET)
Alternative Name
RET
Background
RET, a member of the cadherin superfamily, is one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This protein plays a crucial role in neural crest development, and the gene can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations i are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma.